Current issues & future trends in cryopreservation for advanced therapies
Bibliographic record
Abstract
Three industry experts discuss lessons learned in the cryopreservation sector over the last decade, as well as potential innovative solutions to current challenges within the space. The authors also explore the question of how industry and academia can come together to create these solutions.Jason Acker is the Senior Development Scientist with the Canadian Blood Services’ Centre for Innovation and a Professor in the Department of Laboratory Medicine and Pathology at the University of Alberta, Edmonton, Canada. His research focuses on understanding the response of cells and tissues to ex vivo storage and the development of methods for their preservation and use as therapeutic products. Acker’s blood services laboratory has responsibility for developing scientific and technical evidence to support innovative changes in blood product manufacturing, storage, and utilization at Canadian Blood Services. Through the Canadian Blood Services Centre for Innovation, Acker leads Canadian Blood Services’ efforts to assess new technology, products and processes that can improve the efficiency, quality and safety of blood products in Canada. Acker is author of more than 225 publications, eight book chapters, and holds 12 patents in the area of cell preservation and microfabrication. Acker serves as an Associate Editor for Transfusion and is an editorial board member for four journals and invited reviewer for more than 35 scientific journals. He serves as the Scientific Secretary with the International Society for Blood Transfusion and is a Scientific Member and Co-Lead with the Biomedical Excellence for Safer Transfusion Collaborative. Acker is the past-president and a Fellow of the International Society for Cryobiology and is actively involved in consulting with and advising companies and organizations developing biobanking and cell therapy programs.Allison Hubel is a Professor in Mechanical Engineering at the University of Minnesota and Director of the Technology Leadership Institute where she holds the HW Sweatt Chair. She is President of the Society for Cryobiology. Hubel has studied both basic science and translational issues behind preservation. Her work spans from the study of molecular mechanisms of damage during preservation to the development of technology to improve preservation outcomes. She is the Founder of Evia Bio, a startup company based on the preservation technology developed in her lab. As co-PI for the MN-REACH commercialization hub and faculty lead for the University of Minnesota Great Lakes I-Corps Hub site, Hubel has been involved in working with faculty interested in commercialization of academic research. Hubel has published numerous scientific articles in the field of preservation, and she is the author of, Preservation of Cells: A Practical Manual published in 2018. She is a former deputy editor of Biopreservation and Biobanking and received the Outstanding Achievement in Biobanking Award from ISBER.Sean Werner is the Chief Technology Officer of Cell Processing at BioLife Solutions, a leading provider of bioproduction tools and services to the cell and gene therapy and broader biopharma markets. BioLife acquired Sexton Biotechnologies in 2021 where Sean was President of the company known for providing processing and handling solutions for the cell and gene therapy industry. Sean received his PhD from Purdue University in Biology followed by post-doctoral positions at the Indiana University School of Medicine and Eli Lilly and Company. Sean has previous experience filling various roles in the scientific, global regulatory, and general management functions supporting medical devices, autologous cell therapy, and single use disposable development programs. In his 23 years working in the life science industry, he has guided regenerative medicine research programs, pre-clinical, and clinical testing and submission strategies leading to global commercialization of medical devices and bioprocessing tools and successful initiation of multi-national cell therapy clinical studies.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame distilled prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.
Codex and Gemma teacher scores by category
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.000 |
| Insufficient payload (model declined to judge) | 0.000 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one teacher head, not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".